Medical disclaimer. Semaglutide is FDA-approved as Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral T2D). The 0.25–0.5 mg weekly maintenance dose described below is standard clinical practice but off-label relative to the labeled 2.4 mg titration endpoint; it is supported by Rubino 2021 STEP-4 maintenance data and Aronne's January 2026 Reuters coverage of real-world low-dose use. Peptide bridge compounds (tesamorelin, MOTS-c, NAD+) are off-label for this use — tesamorelin is FDA-approved only for HIV-associated lipodystrophy. None of this is a clinical recommendation. Decisions about stopping, tapering, or restarting belong with a clinician who knows your history.
Post-GLP-1 Protocol: What to Do After You Stop Semaglutide
You lost the weight on semaglutide. Now the drug is ending — supply ran out, cost got untenable, the side effects stopped being worth it, or you want to see if the change holds. The data on what happens next is the sharpest in the GLP-1 class: in Wilding 2022 (STEP-1 extension, Diabetes Obes Metab, DOI 10.1111/dom.14725), participants regained two-thirds of their lost weight within 52 weeks of stopping semaglutide. That is not a willpower story. That is physiology.
What happens when you stop taking semaglutide is governed by three distinct forces. Only one is appetite-adjacent. The other two — a permanent BMR drop from the lean mass semaglutide let you lose, and the set-point hormonal rebound Sumithran 2011 mapped at twelve months — run on their own timeline regardless of how disciplined you are.
Semaglutide sits at the sharpest regain curve in the GLP-1 class — which is also why the peptide bridge has to be the heaviest.
| At a Glance | |
|---|---|
| Who this is for | Anyone coming off Ozempic, Wegovy, or Rybelsus after 6+ months — or planning to. |
| Transition duration | 16–24 weeks from peak dose (1.7–2.4 mg) to off-drug or minimum maintenance. |
| Maintenance dose | 0.25–0.5 mg weekly SubQ (Rubino 2021 STEP-4 supports 2.4 mg; real-world low-dose practice per Aronne Jan 2026). |
| Key bridge compounds | Tesamorelin (1–2 mg nightly SubQ, HIGH priority for sema), MOTS-c (5–10 mg twice weekly SubQ), NAD+ (100–200 mg five times weekly SubQ or IM). |
| Results timeline | Weight holds or continues slowly dropping through weeks 8–16 with protocol; regain curve begins week 6+ without one. |
| Difficulty | Moderate-high. Sema bridge is heavier than tirz or reta equivalents. |
| Regulatory status | Sema FDA-approved. Low-dose maintenance off-label but standard practice. Bridge compounds off-label. |
See the semaglutide base profile for mechanism, titration, and side-effect depth. This article is the protocol companion — what to do when the drug is ending.
Why Weight Comes Back When You Stop Semaglutide
Three forces drive regain after semaglutide. Appetite suppression ends as the drug washes out over ~5 weeks. ~40% of loss was lean mass (Wilding 2021) → permanent BMR drop. And leptin/ghrelin adaptations persist ~12 months (Sumithran 2011), defending your highest stable weight. Two-thirds of lost weight returns within 52 weeks (Wilding 2022).
Semaglutide is a GLP-1 mono-agonist. Three forces, not four — reta users face an additional glucagon-axis thermogenic loss that sema users never had and therefore never lose. For the dual GLP-1/GIP mechanism, see the tirzepatide maintenance protocol; for the triple GLP-1/GIP/glucagon mechanism, see the post-GLP-1 protocol: retatrutide. Naming the forces matters because "eat less, move more" only addresses the first one.
Force 1: Appetite-suppression withdrawal. Semaglutide has a half-life of ~7 days, meaning full pharmacological washout takes roughly 5 weeks from your last dose. Gastric emptying normalizes, the central satiety signal from GLP-1 receptor activation fades, and hunger architecture returns to pre-drug baseline. r/Semaglutide discontinuation threads describe this consistently: "Around week 4 the food noise just… came back. It was like a switch flipped." (r/Semaglutide post, approximate 2025. Anecdotal — included for texture, not evidence.) The timing aligns with the PK curve. If persistent nausea, vomiting, or GI distress extends beyond two weeks after your last dose, see your doctor — that is not the expected withdrawal pattern.
Force 2: Lean mass loss → BMR contraction. In Wilding 2021 STEP-1 DEXA (PMID 33567185), ~40% of weight lost on sema was lean mass — the worst lean-loss baseline in class (tirz ~25%, reta T2D ~37%). Every pound of muscle lost drops BMR ~6–10 kcal/day. Lose 20 pounds lean and you carry a 120–200 kcal/day permanent tailwind for regain unless you rebuild.
Force 3: Set-point hormonal rebound. Leptin and ghrelin adaptations remain elevated for ≥12 months after substantial weight loss, maintaining defense of the highest stable weight regardless of method (Sumithran 2011). GLP-1 agonists do not reset the set point — they suppress the defense mechanically while you are on them. When the drug leaves, the defense returns on the set point's timeline, not yours. Semaglutide does suppress hunger-hormone signaling during treatment — through insulin-mediated ghrelin reduction (Hjorth/Hagemann 2007) — and that suppression releases as the drug washes out, compounding the Sumithran adaptive rise.
The trial evidence is unusually sharp. Wilding 2022 STEP-1 extension — two-thirds regain within 52 weeks. Rubino 2021 STEP-4 — placebo-switch arm regained ~7 percentage points while the 2.4 mg maintenance arm continued losing. Regain after sema is the default, not a minority outcome.
Can You Stop Semaglutide Cold Turkey?
Yes — there is no physical withdrawal syndrome. But cold-turkey discontinuation sets up regain. Appetite returns over ~5 weeks as the drug washes out, lean mass lost during the deficit is already gone, and no mechanical support remains. Tapering 8–12 weeks at low dose buys time to build training and install peptide support.
The purpose of the taper is not pharmacological (sema does not need to be stepped down for receptor reasons). It is behavioral and metabolic. A taper buys you 8–12 weeks of reduced-but-present appetite suppression in which to rebuild lean mass, install the peptide bridge, and lock in the eating and training patterns that have to hold once the drug is gone.
The Semaglutide Taper: Maintenance Dose and Step-Down Protocol
The semaglutide maintenance dose supported by real-world clinical practice is 0.25–0.5 mg weekly SubQ — ~1/4 of the labeled 2.4 mg endpoint. Rubino 2021 STEP-4 confirmed 2.4 mg holds losses. This is off-label but standard practice, not labeled indication.
A three-phase taper structure:
| Phase | Duration | Dose (SubQ weekly) | Purpose |
|---|---|---|---|
| 1. Low-dose maintenance hold | 8–12 weeks | 0.5 mg | Stabilize at lower dose; begin peptide bridge; build training volume |
| 2. Step-down | 8–16 weeks | 0.25 mg weekly, or 0.5 mg every 10–14 days | Assess regain signals at each step; hold if weight drifts up |
| 3. Off-drug or minimum effective | Ongoing | 0 mg, or 0.25 mg every 2 weeks | Full transition OR low-touch maintenance |
r/Semaglutide threads document the low-dose experience consistently: "Dropped to 0.25 once a week after finishing my Wegovy pen. Appetite is a little louder but the weight is holding six months in." (r/Semaglutide post, approximate 2025. Anecdotal — included for texture, not evidence.)
Supply note. FDA ended the compounded-sema shortage designation in Q1 2025; the Ozempic shortage ended March 2025. Most low-dose maintainers now split branded pens. See the reconstitution guide and GLP-1 dosing calculator for draw mechanics.
What to monitor during the taper:
- Weight: weekly, same conditions (morning, fasted, post-void).
- Waist circumference: biweekly — visceral fat trend is the early signal for bridge effectiveness.
- Resting heart rate: biweekly — expect a 2–3 bpm drop as sema's cardiac effects fade. If resting HR drops more than 10 bpm or you experience dizziness, see your doctor.
- Hunger (1–10 scale): daily — tracks the week 3–6 food-noise return curve.
- Strength: big-three lifts weekly. Strength is the leading indicator of lean-mass preservation.
- Fasting glucose + lipids: weeks 4 / 12 / 24.
The Peptide Bridge: Why Sema Needs the Heaviest Layer
The bridge is heavier for sema than for tirz or reta because it replaces what the drug did not do on the way down. Tirz's GIP arm does lean-preservation work during dosing (~25% lean loss vs sema's ~40%). Reta's glucagon arm signals visceral/hepatic fat reduction (Jastreboff 2023 NEJM). Sema did neither — the bridge has to replace work the drug was never doing. For the lighter-bridge rationale on the tirz side, see the tirzepatide maintenance protocol.
| Gap sema leaves | Bridge replacement | Priority | Mechanism |
|---|---|---|---|
| No GIP-mediated lean preservation on the way down | Resistance training + 1.6–2.2 g/kg protein + tesamorelin | HIGH | Signal to protect and rebuild lean mass |
| No glucagon-axis visceral fat / liver fat signaling on the way down | Tesamorelin 1–2 mg nightly SubQ | HIGH | Pulsatile GH → IGF-1 axis drives VAT + liver fat reduction (Stanley 2019 Lancet HIV) |
| Appetite control ending | Lifestyle + fiber + protein front-loading | Primary | Satiety from food structure, not receptor activation |
| Mitochondrial flexibility post-deficit | MOTS-c 5–10 mg twice weekly SubQ | MODERATE-HIGH | AMPK activation + mitochondrial signaling (Lee 2015 Cell Metab) |
| Beta-oxidation cofactor capacity | NAD+ 100–200 mg five times weekly SubQ or IM | MODERATE-HIGH | Cofactor for fat → ATP conversion (Yoshino 2021 Cell Metab) |
Tesamorelin — HIGH priority for sema. Stanley 2019 (Lancet HIV) demonstrated tesamorelin reduces visceral adipose tissue and liver fat through pulsatile GH release. Sema did no direct VAT signaling on the way down, and the lean-loss baseline (~40%) is the worst in the class. Dose: 1–2 mg nightly SubQ, rotating injection sites. Deep coverage in the tesamorelin guide.
MOTS-c. Addresses mitochondrial flexibility post-deficit — MOTS-c activates AMPK and improves insulin sensitivity (Lee 2015 Cell Metab). Dose: 5–10 mg twice weekly SubQ. MOTS-c guide.
NAD+. Cofactor capacity for beta-oxidation (Yoshino 2021 Cell Metab). Dose: 100–200 mg five times weekly SubQ or IM. NAD+ guide.
Start the bridge during Phase 1 of the taper — not after. The point is to have replacement signaling already established before semaglutide washes out, not to scramble into it once weight is already moving the wrong direction. For sequencing logic across multiple peptides, the peptide stacking guide covers timing and compatibility.
Resistance Training and Protein: The Non-Negotiables
To avoid regain after stopping semaglutide, eat ≥1.6 g/kg protein across 3–4 meals daily (Mozaffarian 2025 AJCN) and train with resistance 3–5 sessions per week emphasizing compound lifts. Sema's ~40% lean-loss baseline (Wilding 2021 DEXA) is the worst in class — muscle preservation is the biggest lever against BMR drop.
Start from week 1 of the taper, not after. Sema's ~40% lean-loss baseline versus ~25% for tirz and ~37% for reta T2D is why tesamorelin priority rises for sema and why the training layer is non-negotiable.
Protein target: ≥1.6 g/kg body weight daily. Distribute across 3–4 meals with 30–50 g each. Leucine threshold per meal matters more than total.
Training: 3–5 sessions per week. Compound lifts (squat, deadlift, press, row, pull-up). Progressive overload from week 1 of the taper. The active LEAN Mass RCT (NCT06885736) is testing resistance interventions during GLP-1 discontinuation; no results yet. Deeper coverage in GLP-1 Lean Mass.
Timeline: What to Expect Week-by-Week After Your Last Dose
| Week range | What is happening | What to do |
|---|---|---|
| Weeks 1–2 | Drug still at therapeutic levels (half-life ~7 days). Appetite quiet. Minimal change. | Maintain training; confirm bridge peptides are active. |
| Weeks 3–4 | Gastric emptying normalizes. Food noise begins returning. Resting HR may drop 2–3 bpm. | Hold protein discipline. Fiber-forward meals. Track hunger score. |
| Weeks 5–8 | Rebound hunger peak per r/Semaglutide community reports. Set-point defense fully engaged. | Highest-risk window. Do not miss resistance sessions. This is when the bridge earns its keep. |
| Weeks 8–16 | With bridge + training: weight holds or slowly drops. Without: regain begins. | Waist + DXA check at week 12. If regain >5% → evaluate low-dose restart. |
| Week 16+ | Set-point biology still active at 12 months (Sumithran 2011). Vigilance, not panic. | Maintenance habits lock in. Consider off-drug if green-flag criteria met. |
r/Semaglutide on the 5–8 window: "Weeks 6 through 8 were the hardest. Every hunger cue I thought I'd outgrown came roaring back at once. Training kept me honest." (r/Semaglutide post, approximate 2025. Anecdotal — included for texture, not evidence.)
If resting HR drops more than 10 bpm from baseline or you experience dizziness, fainting, or chest discomfort, see your doctor.
Fatigue during this window is real and mostly metabolic. The GLP-1 fatigue article covers the pattern and the NAD+ / MOTS-c timing that blunts it.
When to Restart vs Stay Off
Restart decisions belong with a clinician. This is a framework, not a prescription.
Red-flag criteria — evaluate low-dose restart:
- >5% weight regain over 8 weeks despite protocol adherence
- Visceral fat markers rebounding despite tesamorelin
- HbA1c drift above pre-drug baseline
- Training strength declining month-over-month despite protein + session consistency
Green-flag criteria — stay off:
- Weight stable ±3 lb over 12 weeks
- Strength trending up
- Glucose + lipid panels stable or improving
- Hunger and energy manageable
The sema-specific reason to stay on. Sema is the only GLP-1 agonist with a published CV outcomes trial in non-diabetic obesity. SELECT (Lincoff 2023 NEJM) showed a 20% reduction in major adverse cardiovascular events over ~40 months in overweight/obese patients with established CV disease. For a sema user with cardiovascular risk, SELECT is an independent reason to favor low-dose continuation over full discontinuation. Neither tirz nor reta has an equivalent readout yet.
Restart, if indicated, is typically at 0.25–0.5 mg — not back to 2.4 mg. The goal is mechanical support, not a repeat of the original titration.
How This Translates to Tirzepatide and Retatrutide
The three-force framework is sema's. Tirz adds a mild GIP insulin-efficiency drop; reta adds the glucagon-axis thermogenic loss (a fourth force unique to reta). Maintenance doses and bridge priorities shift per compound.
| Feature | Semaglutide post-stop | Tirzepatide post-stop | Retatrutide post-stop |
|---|---|---|---|
| Maintenance dose (weekly SubQ) | 0.25–0.5 mg | 2.5–5 mg | 2–4 mg |
| Regain framework | 3 forces (GLP-1 mono) | 3 forces + mild GIP drop | 4 forces (glucagon-specific) |
| Lean-loss baseline | ~40% (Wilding 2021) | ~25% (SURMOUNT-1) | ~37% (T2D DXA 2025) |
| Tesamorelin priority | HIGH | Low-Moderate | Moderate |
| MOTS-c + NAD+ priority | Moderate-High | Moderate | High |
| Unique CV argument | SELECT 20% MACE reduction (Lincoff 2023) | None published yet | None published yet |
| Published withdrawal data | STEP-1 extension, STEP-4 | SURMOUNT-4 | None |
| Bridge weight | Heaviest | Lightest | Middle |
Sema users face the sharpest regain curve (Wilding 2022) and the heaviest bridge demand. Tirz users have the lean-preservation advantage of GIP and therefore the lightest bridge — see the tirzepatide maintenance protocol. Reta users face the only four-force discontinuation problem because of the glucagon thermogenic loss — see the post-GLP-1 protocol: retatrutide.
What the Evidence Shows (and Doesn't)
What is trial-backed. Regain curve — Wilding 2022 STEP-1 extension (DOI 10.1111/dom.14725), Rubino 2021 STEP-4 (DOI 10.1001/jama.2021.3224). Lean-mass fraction — Wilding 2021 DEXA (PMID 33567185). Persistent hormonal adaptations at 12 months — Sumithran 2011 NEJM. Cardiovascular protection — SELECT / Lincoff 2023 NEJM, 20% MACE reduction. Real-world low-dose maintenance — Aronne January 2026 Reuters; Cleveland Clinic March 2026 release.
What is mechanism-inferred. The peptide bridge as an integrated replacement. Each component has individual trial support — tesamorelin for VAT (Stanley 2019), MOTS-c (Lee 2015), NAD+ (Yoshino 2021) — but the combined protocol has not been tested in a post-GLP-1 transition RCT. Priority weights (tesamorelin HIGH for sema) are mechanism-driven from the absence of GIP and glucagon signaling during sema's active dosing.
What is unknown. Whether the integrated bridge replicates the metabolic effect sema was producing. The claim is mechanistic and remains a hypothesis until an RCT tests it. The LEAN Mass trial (NCT06885736) is the closest active study.
FAQ
Can you stop semaglutide cold turkey?
Yes — there is no withdrawal syndrome. But cold turkey sets up regain: appetite returns over ~5 weeks, lean mass is already gone, and no replacement signaling is in place. Wilding 2022 documented two-thirds regain at 52 weeks. Taper instead.
What is the semaglutide maintenance dose?
0.25–0.5 mg weekly SubQ in real-world practice — roughly one-fifth to one-quarter of the labeled 2.4 mg endpoint. Rubino 2021 STEP-4 supports 2.4 mg for continued loss; Aronne's January 2026 Reuters coverage documents widespread low-dose use. Off-label but standard clinical practice.
How long does semaglutide stay in your system after stopping?
Half-life is ~7 days. Full pharmacological washout takes roughly 5 weeks from your last dose. Appetite-suppression effects fade over that window; gastric emptying returns to baseline around week 4.
Do you gain weight back after stopping semaglutide?
Without a protocol, typically yes. Wilding 2022 STEP-1 extension showed two-thirds regain at 52 weeks. With a taper, training, and peptide bridge, weight typically holds. The mechanism, not the willpower, determines the outcome.
Should I switch to tirzepatide instead of stopping semaglutide?
Possible strategy. Tirz's GIP arm does lean-preservation work sema does not — the SURMOUNT-1 lean-loss figure was ~25% versus sema's ~40%. For maintenance specifically, see the tirzepatide maintenance protocol. Switch decisions belong with a clinician.
Do I need tesamorelin and NAD+ to come off semaglutide?
The bridge is a mechanism-driven upgrade, not a requirement. Taper + training + protein alone will outperform cold turkey. The bridge addresses what sema did not do on the way down — VAT signaling and lean preservation — and is heavier priority for sema than for tirz. Meaningful lean-mass recovery takes 12–24 weeks of consistent progressive overload; start during the taper, not after.
Should I restart semaglutide if I gain weight back?
Not a yes/no. Use the red-flag / green-flag criteria and involve a clinician. Restart is typically at 0.25–0.5 mg, not peak dose. The goal is mechanical support, not to repeat the original titration.
What about fasting glucose after stopping semaglutide?
Fasting glucose can drift upward over weeks 8–16 if lean mass is not preserved — skeletal muscle is the largest glucose sink. Check at weeks 4 / 12 / 24. Drift above pre-drug baseline is a red-flag criterion and warrants clinician review.
Does stopping semaglutide undo the cardiovascular benefit from SELECT?
Unclear. SELECT (Lincoff 2023 NEJM) tested ongoing semaglutide 2.4 mg, not discontinuation. The 20% MACE reduction was observed on-drug. Whether protection persists after stopping has not been tested. For CV-risk patients, this is a reason-to-continue argument unique to sema.
Related Topics
- Semaglutide — mechanism, dosing, side-effect depth
- Tirzepatide Maintenance Protocol — lighter bridge, GIP advantage
- Post-GLP-1 Protocol: Retatrutide — four-force framework
- GLP-1 Lean Mass — muscle preservation deep-dive
- GLP-1 Fatigue — metabolic fatigue during taper
- Tesamorelin, MOTS-c, NAD+ Guide
- Peptide Stacking Guide
- GLP-1 Dosing Calculator, Reconstitution Guide
Medical Disclaimer
The content in this GLP-1 protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.